You are viewing: India Oral Proteins & Peptides Market analysis

The India Oral Proteins & Peptides Market was valued at $133.9 Million in 2025 and projected to reach to $297.4 Million by 2030, representing a compound annual growth rate of 17.3%. India's oral proteins and peptides market is positioned for substantial growth over the next five years, supported by increasing healthcare expenditure, rising chronic disease burden, and growing pharmaceutical manufacturing capabilities.

India Oral Proteins & Peptides Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

India Oral Proteins & Peptides Market Trends and Insights

  • This 17.3% compound annual growth rate reflects India's rising healthcare investments, increasing prevalence of chronic diseases, and growing adoption of advanced pharmaceutical formulations.
  • India's large population and expanding middle class are driving demand for innovative oral delivery systems that improve bioavailability and patient compliance. The Indian market benefits from a strong generic pharmaceutical base and cost-effective manufacturing capabilities that position India as a key player in oral protein and peptide development.
  • India's regulatory framework improvements and investment in biotechnology infrastructure are accelerating market penetration.
  • Between 2025 and 2030, India is expected to capture significant market share as domestic and international companies expand their oral protein portfolios to address diabetes, obesity, and gastrointestinal disorders..

Key Market Statistics

  • CAGR (2025-2030) 17.3% CAGR
  • Market Size, 2025 ~USD 133.9 Million
  • Forecast, 2030 ~USD 297.4 Million
  • Country India

India Oral Proteins & Peptides Market Overview

Rapid Market Expansion :

India's oral proteins and peptides market is projected to grow from USD 133.9 million in 2025 to USD 297.4 million by 2030, representing a robust 17.3% CAGR driven by increasing healthcare spending and pharmaceutical innovation.

Chronic Disease Prevalence :

Rising incidence of diabetes, cardiovascular diseases, and metabolic disorders in India is accelerating demand for advanced oral protein and peptide-based therapeutics as preferred treatment options.

Growing Middle-Class Healthcare Adoption :

India's expanding middle class with increasing disposable income is driving higher adoption of premium pharmaceutical formulations, including oral proteins and peptides for chronic disease management.

Government Healthcare Initiatives :

Government programs like Ayushman Bharat and increased pharmaceutical R&D investments are strengthening India's healthcare infrastructure and creating favorable conditions for oral protein and peptide market growth.

India Oral Proteins & Peptides Market Dynamics

  • The country's large population base and expanding middle class present significant opportunities for market penetration and product adoption.
  • Government initiatives promoting healthcare accessibility and domestic pharmaceutical innovation are expected to accelerate market development.
  • Additionally, India's role as a global pharmaceutical hub enhances its capacity to develop and commercialize advanced oral formulations, positioning the market for sustained expansion through 2030..

Related Ecosystem

Pharmaceuticals

Top Technologies
  • Bioreactors
  • Analytical Testing
  • Bioanalytical Testing Services
  • Cell Counters
  • Data Management Services
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • SANOFI
  • Pfizer Inc.
  • NOVARTIS

    Key Takeaways

    • India's oral proteins & peptides market is valued at USD 133.9 million in 2025 and will nearly double to USD 297.4 million by 2030.
    • India's 17.3% CAGR outpaces many developed markets, driven by rising chronic disease prevalence and healthcare modernization.
    • India's cost-effective manufacturing and generic pharmaceutical expertise position the country as a global hub for oral peptide development.
    • India's expanding middle class and improved regulatory environment are key catalysts for market growth through 2030.

    Oral Proteins & Peptides Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment OBESITY & OVERWEIGHT (Therapeutic Area)
    Forecast Period 2025–2030
    Growth Rate CAGR of 22.1% from 2025 to 2030
    Largest Segment TABLETS (Formulation)
    Market Size Base Year (Billions) ~USD 8.84 (2025)
    Revenue Forecast (Billions) ~USD 24 (2030)
    Segments Covered Molecule, Drug Class, Formulation, Therapeutic Area, End User

    India Oral Proteins & Peptides Market Report Segmentation

    5 segment dimensions are covered across the global market.

    By Molecule

    • Calcitonin
    • Linaclotide
    • Other Molecules
    • Plecanatide
    • Semaglutide
    • Trofinetide
    • Voclosporin

    By Drug Class

    • Cgrp Receptor Antagonists
    • Cnis
    • Gc-C Agonists
    • Glp-1 Receptor Agonists
    • Gpe
    • Other Drug Classes

    By Formulation

    • Capsules
    • Oral Solutions
    • Tablets

    By Therapeutic Area

    • Cns Disorders
    • Diabetes
    • Gastroenterology
    • Genetic Disorders
    • Nephrology
    • Obesity & Overweight
    • Other Therapeutic Areas

    By End User

    • Home Care Settings
    • Hospitals & Specialty Clinics
    • Long-Term Care Facilities

    INDIA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    HOME CARE SETTINGS44.581.895.9111.7135.7158184214.517.5
    HOSPITALS & SPECIALTY CLINICS12.823.126.630.536.441.747.854.715.5
    LONG-TERM CARE FACILITIES18.233.238.744.85462.572.483.916.7
    TOTAL75.5138.1161.2186.9226.1262.2304.2353.117

    Target Audience

    • Pharmaceutical Manufacturers : Manufacturers need India-specific market data to develop localized product strategies, identify manufacturing opportunities, and plan market entry or expansion in this high-growth oral proteins and peptides segment.
    • Healthcare Investors & PE Firms : Investment professionals require detailed India market analysis to evaluate investment opportunities, assess market potential, and make informed capital allocation decisions in the pharmaceutical and biotech sectors.
    • Medical Device & Pharma Distributors : Distributors need India market insights to understand demand patterns, identify growth segments, and optimize distribution strategies for oral protein and peptide products across Indian healthcare channels.
    • Healthcare Consultants & Advisors : Consultants require comprehensive India market data to provide strategic recommendations to clients, support business development initiatives, and guide market entry strategies in the oral proteins sector.
    • Government & Policy Makers : Policy officials and healthcare administrators need market intelligence to inform healthcare policy decisions, pharmaceutical regulations, and investment priorities aligned with India's healthcare development goals.

    Key Companies in the India Oral Proteins & Peptides Market

    CompanyHQOwnershipStrongest segments
    NOVO NORDISK A/SDenmarkPublic CompanyObesity and Diabetes Care – GLP-1 injectables (including Wegovy),Obesity and Diabetes Care – oral GLP-1 and other diabetes therapies,Rare Disease – rare blood and endocrine disorders,
    ABBVIE INC.United StatesPublic CompanyImmunology (Skyrizi, Rinvoq and related autoimmune/inflammatory),Oncology/Hematology (Imbruvica, Venclexta, Elahere, Epkinly, Emrelis),Neuroscience & CNS (Vraylar, Duodopa, Vyalev and related),
    PFIZER INC.IndiaPublic CompanyInternal medicine (CV, respiratory, gastro, multivitamins, neuroscience, women’s health),Vaccines,Injectables and anti-infectives,
    BAUSCH HEALTH COMPANIES INC.CanadaPublic CompanyBausch + Lomb (eye health),Salix (gastroenterology and hepatology),Solta Medical (aesthetic medical devices),
    ACADIA PHARMACEUTICALS INC.United StatesPublic CompanyNUPLAZID (Parkinson’s disease psychosis),DAYBUE / trofinetide (Rett syndrome),Pipeline and other revenues,
    AURINIA PHARMACEUTICALS INC.CanadaPublic CompanyLUPKYNIS (voclosporin) for lupus nephritis,Other pipeline and collaboration revenue (including aritinercept-related),
    MERCK & CO., INC.United StatesPublic CompanyOncology (Keytruda, Keytruda Qlex, Welireg, ADC collaborations, Lynparza co-commercialization),Vaccines (Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23),Hospital & Specialty (Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/Verquvo, Ohtuvayre),
    SWK HOLDINGSUnited StatesPrivate Investment FirmHealthcare venture debt (biopharma, medtech, diagnostics, life science tools),Healthcare services and HIT lending,Technology and SaaS venture debt (non-healthcare),
    ENTERA BIO LTD.IsraelPublic CompanyEB613 – oral teriparatide (osteoporosis, stress fractures),EB612 – hypoparathyroidism peptide replacement,EB618 – GLP-1/glucagon dual agonist (obesity, metabolic, fibrotic),
    ASTRAZENECA PLCUnited KingdomPublic CompanyOncology (Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Imjudo, others),Cardiovascular, Renal & Metabolism (Farxiga/Forxiga, Brilinta/Brilique, Crestor, diabetes combinations),Respiratory & Immunology (Symbicort, Fasenra, Tezspire, Breztri, Airsupra, others),

    NOVO NORDISK A/S

    Novo Nordisk A/S is a Danish pharmaceutical company founded in 1923 with 67,900 employees. Operating as a public company, it is a major player in the global pharmaceutical industry.

    ABBVIE INC.

    AbbVie Inc. is a United States-based public pharmaceutical company established in 2012 with 57,000 employees. The company operates in the pharmaceutical sector with significant global operations.

    PFIZER INC.

    Pfizer Inc. operates as a public company in India with 1,244 employees, having been established in 1950. The company is engaged in pharmaceutical operations in the Indian market.

    BAUSCH HEALTH COMPANIES INC.

    Bausch Health Companies Inc. is a Canadian public company with 20,300 employees operating in the pharmaceutical and healthcare sectors.

    ACADIA PHARMACEUTICALS INC.

    Acadia Pharmaceuticals Inc. is a United States-based public pharmaceutical company founded in 1993 with 797 employees. The company focuses on pharmaceutical development and commercialization.

    AURINIA PHARMACEUTICALS INC.

    Aurinia Pharmaceuticals Inc. is a Canadian public company established in 1993 with 128 employees. The company operates in the pharmaceutical sector.

    MERCK & CO., INC.

    Merck & Co., Inc. is a United States-based public pharmaceutical company founded in 1891 with 74,000 employees. It is one of the world's largest pharmaceutical manufacturers.

    SWK HOLDINGS

    SWK Holdings is a United States-based private investment firm founded in 1996 with 9 employees.

    ENTERA BIO LTD.

    Entera Bio Ltd. is an Israeli public company founded in 2009 with 21 employees operating in the pharmaceutical sector.

    ASTRAZENECA PLC

    AstraZeneca PLC is a United Kingdom-based public pharmaceutical company founded in 1992 with 96,100 employees. It is a major global pharmaceutical manufacturer.

    Reasons to Buy this Report

    • Market Size & Growth Validation : Access precise market valuation data for India (USD 133.9M in 2025) with verified 17.3% CAGR projections through 2030, enabling accurate business planning and investment decisions specific to the Indian market.
    • Competitive Landscape Intelligence : Understand India-specific market dynamics, key players, and competitive positioning to identify market entry opportunities and strategic partnerships within the rapidly expanding oral proteins and peptides sector.
    • Regulatory & Healthcare Insights : Gain comprehensive understanding of India's regulatory environment, government healthcare initiatives, and reimbursement policies affecting oral protein and peptide product commercialization and market adoption.
    • Customer Segmentation Analysis : Identify and target high-potential customer segments in India including hospitals, clinics, pharmaceutical distributors, and healthcare providers with tailored market strategies and product positioning.
    • Growth Driver Identification : Leverage detailed analysis of India-specific growth catalysts including rising chronic disease prevalence, middle-class expansion, and healthcare spending to capitalize on emerging market opportunities.

    Frequently asked questions

    What is the current size of India's oral proteins and peptides market?

    India's oral proteins and peptides market is valued at USD 133.9 million in 2025 and is projected to grow to USD 297.4 million by 2030.

    What is the expected growth rate for India's oral proteins and peptides market?

    India's oral proteins and peptides market is expected to grow at a compound annual growth rate (CAGR) of 17.3% from 2025 to 2030.

    What factors are driving growth in India's oral proteins and peptides market?

    India's market growth is driven by rising chronic disease prevalence, healthcare infrastructure investments, cost-effective manufacturing capabilities, regulatory improvements, and increasing adoption of advanced oral delivery technologies.

    Why is India positioned as a key player in oral peptide development?

    India's strong generic pharmaceutical base, cost-effective manufacturing, skilled workforce, and improving regulatory framework make it an attractive hub for oral protein and peptide research and production.

    Which therapeutic areas are driving demand in India's oral proteins and peptides market?

    India's market is primarily driven by demand in diabetes management, obesity treatment, and gastrointestinal disorder therapies, reflecting the country's disease burden and healthcare priorities.

    RESEARCH METHODOLOGY

    This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global oral proteins and peptides market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

    Secondary Research

    Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the oral proteins and peptides market. The secondary sources used for this study include the World Health Organization (WHO), National Institutes of Health (NIH), United States Food and Drug Administration (US FDA), European Medicines Agency (EMA), National Center for Biotechnology Information (NCBI), BioPharm International, International Diabetes Federation, ScienceDirect, ClinicalTrials.gov, PubMed, European Federation of Pharmaceutical Industries and Associations (EFPIA), European Lead Factory (ELF), India Brand Equity Foundation (IBEF), UK Research Partnership Investment Fund (UKRPIF), Pharmaceutical Research and Manufacturers of America (PhRMA), Eurostat, and Factiva; research journals; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; press releases; and trade, business, professional associations. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

    Primary Research

    Extensive primary research was conducted after acquiring basic knowledge about the global oral proteins and peptides market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side, such as pharmaceutical and biotechnology companies, CROs, CMOs, and academic & research institutes, and experts from the supply side, such as C-level and D-level executives, product managers, marketing & sales managers of key manufacturers, distributors, and channel partners. These interviews were conducted across six major regions, including the Asia Pacific, North America, Europe, Latin America, the Middle East, and Africa. Approximately 70% and 30% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

    The following is a breakdown of the primary respondents:

    Oral Proteins and Peptides Market

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The bottom-up approach was used to estimate and validate the total size of the oral proteins and peptides market. These methods were also extensively utilized to estimate the size of various subsegments within the market. The research methodology used to estimate the market size includes the following:

    • The list of approved oral proteins and peptides was identified through extensive secondary and primary research.
    • The oral protein and peptide products in the pipeline were identified from clinical trial registries and from secondary and primary research related to peptide and protein therapeutics.
    • The revenues generated from these oral proteins and peptides were determined through annual reports and secondary sources (including paid databases).
    • The products were categorized according to market segments. Percentage shares and splits were calculated based on revenue contributions for each segment. This information was validated using secondary sources and insights from industry experts.
    • All assumptions, approaches, and individual shares/revenue estimates were validated through expert interviews.

    Global Oral Proteins and Peptides Market Size: Bottom-up Approach

    Oral Proteins and Peptides Market

    Data Triangulation

    After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

    Market Definition

    Oral proteins and peptides are therapeutic drugs made from proteins or peptides (short chains of amino acids) that are meant to be taken by mouth. These biologically active molecules are designed to treat a variety of medical conditions, including chronic diseases such as diabetes, hormonal disorders, and autoimmune disorders.

    Stakeholders

    • Pharmaceutical & biotechnology companies
    • Hospitals
    • Specialty clinics
    • Long-term care facilities
    • Patient advocacy organizations
    • Academic researchers and government research organizations
    • Private research institutes
    • Contract manufacturing organizations (CMOs)
    • Contract research organizations (CROs)
    • Venture capitalists

    Report Objectives

    • To define, describe, and forecast the oral proteins and peptides market based on molecule, drug class, therapeutic area, formulation, end user, and region
    • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
    • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall oral proteins and peptides market
    • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to six main regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
    • To profile the key players in the oral proteins and peptides market and comprehensively analyze their product portfolios, market positions, and core competencies
    • To track and analyze competitive developments in the oral proteins and peptides market, such as acquisitions, product launches/approvals, expansions, agreements, partnerships, and collaborations
    • To benchmark players within the oral proteins and peptides market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business strategy and product strategy

     

    Get the Full Oral Proteins & Peptides Market Report

    Full forecast, segment splits, and company analysis for all Oral Proteins & Peptides Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status